GlassScriptPhysician profile
Amber D Masse
NPI 1235208687
$16,746.86
in general payments reported to CMS, 2019-2025
25 companies · $510 in 2025
The $510 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11K · 2022: $4,159 · 2023: $453 · 2024: $575 · 2025: $510.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,538.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,537.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $14,177.65 | 2021-2025 | |
| Medtronic, INC. | $490.04 | 2021-2025 | Synchromedii |
| Astellas Pharma US INC | $460.55 | 2021-2023 | Veozah |
| Scynexis, INC. | $345.53 | 2022 | |
| Lilly USA, LLC | $261.81 | 2021-2025 | Mounjaro, Zepbound |
| Axsome Therapeutics, INC. | $217.29 | 2024-2025 | Auvelity |
| Astrazeneca Pharmaceuticals LP | $168.24 | 2022-2025 | Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $111.02 | 2021-2025 | Xifaxan |
| Novo Nordisk INC | $108.36 | 2021-2023 | Ozempic, Rybelsus |
| Teva Pharmaceuticals USA, INC. | $91.02 | 2021-2025 | Ajovy |
| Exeltis, USA INC. | $43.58 | 2022-2023 | Slynd |
| Amgen INC. | $35.94 | 2021 | |
| Pfizer INC. | $31.83 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $23.26 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.57 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urovant Sciences INC | $21.79 | 2022 | |
| Coopersurgical, INC. | $20.63 | 2021 | |
| Daiichi Sankyo INC. | $19.47 | 2022 | |
| Abbott Laboratories | $16.50 | 2023 | Freestyle Libre 3 |
| Millicent US INC | $16.42 | 2021 | |
| Lundbeck LLC | $15.79 | 2022 | |
| Allergan, INC. | $13.96 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.50 | 2022 | |
| Impel Pharmaceuticals INC. | $12.16 | 2022 | |
| Mayne Pharma Commercial LLC | $7.95 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Masse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.